



PHYSICIANS' DESK REFERENCE®

Medical Consultant

Ronald Arky, MD, Charles S. Davidson Professor of Medicine and Master, Francis Weld Peabody Society, Harvard Medical School

Vice President of Directory Services: Stephen B. Greenberg

Director of Product Management: David P. Reiss

Senior Product Manager: Mark A. Friedman

Associate Product Manager: Bill Shaughnessy

Director of Sales: Dikran N. Barsamian

National Sales Manager: Anthony Sorce

National Account Manager: Don Bruccoleri

Account Managers:

Marion Gray, RPh

Lawrence C. Keary

Jeffrey F. Pfohl

Christopher N. Schmidt

Stephen M. Silverberg

Suzanne E. Yarow, RN

National Sales Manager, Trade Group: Bill Gaffney

Director of Direct Marketing: Michael Bennett

Direct Marketing Manager: Lorraine M. Loening

Promotion Manager: Donna R. Lynn

Director, Professional Support Services: Mukesh Mehta, RPh

Senior Drug Information Specialist: Thomas Fleming, RPh

Drug Information Specialist: Maria Deutsch, MS, RPh, CDE

Editor, Special Projects: David W. Sifton

Vice President of Production: David A. Pitler

Director of Print Purchasing: Marjorie A. Duffy

Director of Operations: Carrie Williams

Manager of Production: Kimberly H. Vivas

Senior Production Coordinators: Amy B. Brooks, Dawn McCall

Production Coordinator: Mary Ellen R. Breun

PDR Data Manager: Jeffrey D. Schaefer

Senior Format Editor: Gregory J. Westley

Index Editors: Johanna M. Mazur, Robert N. Woerner

Art Associate: Joan K. Akerlind

Senior Digital Imaging Coordinator: Shawn W. Cahill

Digital Imaging Coordinator: Frank J. McElroy, III

Electronic Publishing Designer: Robert K. Grossman

Fulfillment Managers: Stephanie DeNardi, Kenneth Siebert



Copyright © 1999 and published by Medical Economics Company, Inc. at Montvale, NJ 07645-1742. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. PHYSICIANS' DESK REFERENCE®, PDR®, PDR For Nonprescription Drugs®, PDR For Ophthalmology®, Pocket PDR®, and The PDR® Family Guide to Prescription Drugs® are registered trademarks used herein under license. PDR Companion Guide™, PDR® for Herbal Medicines™, PDR® Medical Dictionary™, PDR® Nurse's Handbook™, PDR® Nurse's Dictionary™, The PDR® Family Guide Encyclopedia of Medical Care™, PDR® Electronic Library™, and PDR® Drug Interactions, Side Effects, Indications, Contraindications System™ are trademarks used herein under license.

Officers of Medical Economics Company: *President and Chief Executive Officer:* Curtis B. Allen; *Vice President, New Media:* L. Suzanne BeDell; *Vice President, Corporate Human Resources:* Pamela M. Bilash; *Vice President and Chief Information Officer:* Steven M. Bressler; *Senior Vice President, Finance, and Chief Financial Officer:* Thomas W. Ehardt; *Vice President, Directory Services:* Stephen B. Greenberg; *Vice President, New Business Planning:* Linda G. Hope; *Executive Vice President, Healthcare Publishing and Communications:* Thomas J. Kelly; *Executive Vice President, Magazine Publishing:* Lee A. Maniscalco; *Vice President, Group Publisher:* Terrence W. Meacock; *Vice President, Production:* David A. Pitler; *Vice President, Group Publisher:* Thomas C. Pizor; *Vice President, Magazine Business Management:* Eric Schlett; *Senior Vice President, Operations:* John R. Ware



Printed on recycled paper

ISBN: 1-56363-288-8

KASHIV1044
IPR of Patent No. 9,492,392

ORTHO DIENESTROL CREAM (Ortho-McNeil Pharmaceutical).....	2212
◆ ORTHO TRI-CYCLEN 21 TABLETS (Ortho-McNeil Pharmaceutical).....	328, 2229
ORTHO TRI-CYCLEN 28 TABLETS (Ortho-McNeil Pharmaceutical).....	2229
◆ ORTHO-CEPT 21 TABLETS (Ortho-McNeil Pharmaceutical).....	328, 2204
ORTHO-CEPT 28 TABLETS (Ortho-McNeil Pharmaceutical).....	2204
ORTHOCLONE OKT3 STERILE SOLUTION (Ortho Biotech).....	2160
◆ ORTHO-CYCLEN 21 TABLETS (Ortho-McNeil Pharmaceutical).....	328, 2229
ORTHO-CYCLEN 28 TABLETS (Ortho-McNeil Pharmaceutical).....	2229
◆ ORTHO-EST TABLETS (Women First HealthCare).....	343, 3253
◆ ORTHO-NOVUM 1/35 □ 21 TABLETS (Ortho-McNeil Pharmaceutical).....	328, 2221
ORTHO-NOVUM 1/35 □ 28 TABLETS (Ortho-McNeil Pharmaceutical).....	2221
ORTHO-NOVUM 1/50 □ 21 TABLETS (Ortho-McNeil Pharmaceutical).....	2215
◆ ORTHO-NOVUM 1/50 □ 28 TABLETS (Ortho-McNeil Pharmaceutical).....	328, 2215
ORTHO-NOVUM 7/7/7 □ 21 TABLETS (Ortho-McNeil Pharmaceutical).....	2221
◆ ORTHO-NOVUM 7/7/7 □ 28 TABLETS (Ortho-McNeil Pharmaceutical).....	328, 2221
ORTHO-NOVUM 10/11 □ 21 TABLETS (Ortho-McNeil Pharmaceutical).....	2221
◆ ORTHO-NOVUM 10/11 □ 28 TABLETS (Ortho-McNeil Pharmaceutical).....	328, 2221
◆ ORUDIS CAPSULES (Wyeth-Ayerst).....	344, 3350
◆ ORUVAIL CAPSULES (Wyeth-Ayerst).....	344, 3350
OS-CAL 250 + D, 500, 500 + D, AND 500 CHEWABLE TABLETS (SmithKline Beecham Consumer).....	□
OS-CAL FORTIFIED TABLETS (SmithKline Beecham Consumer).....	□
OSTIDERM (Pedinol).....	2354
OSTIDERM ROLL-ON (Pedinol).....	2354
OTIC DOMEBORO SOLUTION (Bayer).....	667
◆ OVCON 35 TABLETS (Bristol-Myers Squibb).....	307, 845
OVCON 50 TABLETS (Bristol-Myers Squibb).....	845
◆ OVRAL TABLETS (Wyeth-Ayerst).....	344, 3353
◆ OVRAL-28 TABLETS (Wyeth-Ayerst).....	344, 3354
OVRETTE TABLETS (Wyeth-Ayerst).....	3354
OXANDRIN TABLETS (Bio-Technology).....	866
OXANDROLONE Oxandrin Tablets (Bio-Technology).....	866
OXAPROZIN Daypro Caplets (Searle).....	337, 2953
OXAZEPAM Serax Capsules (Wyeth-Ayerst)..... Serax Tablets (Wyeth-Ayerst)..... Oxazepam Capsules (Geneva).....	345, 3383 345, 3383 1076
OXICANAZOLE NITRATE Oxistat Cream (Glaxo Wellcome)..... Oxistat Lotion (Glaxo Wellcome).....	313, 1194 313, 1194
◆ OXISTAT CREAM (Glaxo Wellcome).....	313, 1194
◆ OXISTAT LOTION (Glaxo Wellcome).....	313, 1194
OXSORALEN LOTION 1% (ICN)	1373
◆ OXSORALEN-ULTRA CAPSULES (ICN)	317, 1374

◆ Shown in Product Identification Guide

OXTRIPHYLLINE Cholestyl SA Extended-Release Tablets (Warner Chilcott Professional Products).....	342, 3208
OXYBENZONE DML Facial Moisturizer with Sunscreen (Persón & Covey)..... Eucerin Plus For The Face SPF 15 (Beiersdorf)..... Solaquin Forte 4% Cream (ICN)..... Solbar PF Cream SPF 50 (PABA Free) (Persón & Covey)..... Solbar PF Liquid SPF 30 (Persón & Covey)..... Lubriderm Daily UV Lotion with Sunscreen (Warner-Lambert Consumer).....	2360 702 1365 2361 2361 3215
OXYBUTYRIN CHLORIDE Ditropan Tablets and Syrup (Alza)..... Oxybutynin Chloride Tablets (Watson).....	511 3216
OXYCODONE HYDROCHLORIDE OxyContin Tablets (Purdue Pharma)..... OxyFast Oral Concentrate Solution (Purdue Pharma)..... OxyIR Capsules (Purdue Pharma)..... Percocet Tablets (Endo Labs)..... Percodan Tablets (Endo Labs)..... Percodan-Demi Tablets (Endo Labs)..... Percolone Tablets (Endo Labs)..... Roxicodone Tablets, Oral Solution & Intensol (Roxane)..... Tylox Capsules (Ortho-McNeil Pharmaceutical)..... Endocet Tablets, USP CII (Endo Generics)..... Endodan Tablets, USP CII (Endo Generics)..... Oxycodone and Acetaminophen Tablets, USP (Watson)..... Oxycodone and Aspirin Tablets, USP (Watson)..... Oxycodone Hydrochloride Tablets, USP (Watson)..... Roxicet 5/500 Caplets (Roxane)..... Roxicet Tablets & Oral Solution (Roxane)..... Roxicap Capsules (Roxane)..... Roxiciprin Tablets (Roxane).....	333, 2569 333, 2574 333, 2574 310, 984 310, 985 310, 985 310, 986 2764 329, 2253 971 971 3216 3216 3216 2764 2764 2743 2743
OXYCODONE TEREPHTHALATE Percodan Tablets (Endo Labs)..... Percodan-Demi Tablets (Endo Labs)..... Endodan Tablets, USP CII (Endo Generics)..... Roxiciprin Tablets (Roxane).....	310, 985 310, 985 971 2743
◆ OXYCONTIN TABLETS (Purdue Pharma).....	333, 2569
◆ OXYFAST ORAL CONCENTRATE SOLUTION (Purdue Pharma).....	333, 2574
◆ OXYIR CAPSULES (Purdue Pharma).....	333, 2574
OXYMETHOLONE Anadrol-50 Tablets (Unimed).....	341, 3175
OXYMORPHONE HYDROCHLORIDE Numorphan Injection (Endo Labs)..... Numorphan Suppositories (Endo Labs).....	982 982
OXYQUINOLINE SULFATE Aci-Jel Therapeutic Vaginal Jelly (Ortho-McNeil Pharmaceutical).....	2179
OXYTETRACYCLINE Tetracycline Intramuscular Solution (Pfizer).....	2412
OXYTETRACYCLINE HYDROCHLORIDE Tetra-Cortril Ophthalmic Suspension (Pfizer)..... Tetracycline with Polymyxin B Sulfate Ophthalmic Ointment (Pfizer)..... Urobiotic-250 Capsules (Pfizer).....	2412 2414 2424

P

PACAPS CAPSULES (Lunsco).....	1649
◆ PACERONE TABLETS (Upsher-Smith).....	341, 3181
PACLITAXEL Taxol Injection (Bristol-Myers Squibb Oncology/Immunology).....	308, 798
PADIMATE O (OCTYL DIMETHYL PABA) Solaquin Forte 4% Cream (ICN).....	1365

Solaquin Forte 4% Gel (ICN).....	1365
PALIVIZUMAB Synagis Intramuscular (MedImmune).....	1720
PAMABROM Lurline PMS Tablets (Fielding).....	1011
◆ PAMELOR CAPSULES (Novartis).....	325, 2070
PAMELOR SOLUTION (Novartis).....	2070
PAMIDRONATE DISODIUM Aredia for Injection (Novartis).....	324, 1995
◆ PANAFIL OINTMENT (Rystan).....	335, 2770
◆ PANAFIL-WHITE OINTMENT (Rystan).....	335, 2770
PANALGESIC GOLD CREAM (ECR)	960
PANALGESIC GOLD TOPICAL LIQUID (ECR)	960
◆ PANCREASE CAPSULES (Ortho-McNeil Pharmaceutical).....	328, 2237
◆ PANCREASE MT CAPSULES (Ortho-McNeil Pharmaceutical).....	328, 2238
PANCREATIN Donnazyme Tablets (Robins).....	334, 2637
PANCRELIPASE Cotazym Capsules (Organon)..... Creon 5 Capsules (Solvay)..... Creon 10 Capsules (Solvay)..... Creon 20 Capsules (Solvay)..... Ku-Zyme HP Capsules (Schwarz)..... Pancrease Capsules (Ortho-McNeil Pharmaceutical)..... Pancrease MT Capsules (Ortho-McNeil Pharmaceutical)..... Ultras Capsules (Scandipharm)..... Ultras MT Capsules (Scandipharm)..... Viokase Powder (Axcen)..... Viokase Tablets (Axcen)..... Zymase Capsules (Organon)..... Cotazym-S Capsules (Organon).....	326, 2120 340, 3110 340, 3110 340, 3110 2908 328, 2237 328, 2238 336, 2815 336, 2816 620 305, 620 327, 2157 326, 2121
PANCURONIUM BROMIDE Pancuronium Bromide Injection (Elkins-Sinn)..... Pancuronium Bromide Injection (Astra)..... Pancuronium Bromide Injection (Baxter)..... Pavulon Injection (Organon).....	963 581 629 2146
◆ PANDEL CREAM (Savage).....	336, 2814
PANGLOBLIN INTRAVENOUS (American Red Cross).....	521
PANHEMATIN FOR INJECTION (Abbott).....	469
PANOXYL 5 ACNE GEL (Stiefel).....	3133
PANOXYL 10 ACNE GEL (Stiefel).....	3133
PANOXYL AQ 2 1/2 ACNE GEL (Stiefel).....	3133
PANOXYL AQ 5 ACNE GEL (Stiefel).....	3133
PANOXYL AQ 10 ACNE GEL (Stiefel).....	3133
PANTOTHENATE, CALCIUM (see under: CALCIUM PANTOTHENATE)	
PANTOTHENIC ACID (see under: CALCIUM PANTOTHENATE)	
PAPAIN Accuzyme Debriding Ointment (Healthpoint)..... Panafil Ointment (Rystan)..... Panafil-White Ointment (Rystan).....	315, 1287 335, 2770 335, 2770
PARA-AMINO BENZOIC ACID Mega-B Tablets (Arco).....	545
◆ PARAFON FORTE DSC CAPLETS (Ortho-McNeil Pharmaceutical).....	328, 2239
◆ PARAGARD T 380A INTRAUTERINE COPPER CONTRACEPTIVE (Ortho-McNeil Pharmaceutical).....	328, 2239
◆ PARAPLATIN FOR INJECTION (Bristol-Myers Squibb Oncology/Immunology).....	308, 789

PARCODE PRODUCT LIST (Parke-Davis).....	2265
PARPECTOLIN SUSPENSION (Rhône-Poulenc Rorer).....	2580
PARICALCITOL Zemlar Injection (Abbott).....	479
◆ PARLODEL CAPSULES (Novartis).....	325, 2072
◆ PARLODEL SNAPTABS (Novartis).....	325, 2072
◆ PARNATE TABLETS (SmithKline Beecham).....	339, 3076
PAROXETINE HYDROCHLORIDE Paxil Oral Suspension (SmithKline Beecham)..... Paxil Tablets (SmithKline Beecham).....	3078 339, 3078
PASER GRANULES (Jacobus).....	1417
PATANOL OPTHALMIC SOLUTION (Alcon).....	491
PAVULON INJECTION (Organon).....	2146
PAXIL ORAL SUSPENSION (SmithKline Beecham).....	3078
◆ PAXIL TABLETS (SmithKline Beecham).....	339, 3078
◆ PCE DISPERTAB TABLETS (Abbott).....	303, 470
PECTIN Kaolin-Pectin Suspension (Roxane).....	2743
PEDIACOF COUGH SYRUP (Sanofi).....	2794
PEDIAFLOR DROPS (Ross).....	2743
PEDIALYTE ORAL ELECTROLYTE MAINTENANCE SOLUTION (Ross).....	2736
PEDIAPRED ORAL SOLUTION (Medeva).....	1703
PEDIASURE COMPLETE LIQUID NUTRITION (Ross).....	2739
PEDIAZOLE SUSPENSION (Ross).....	2737
PEDI-BORO SOAK PAKS (Pedinol).....	2354
PEDI-DRI TOPICAL POWDER (Pedinol).....	2354
PEDIOTIC SUSPENSION STERILE (Monarch).....	1941
PEDI-PRO TOPICAL POWDER (Pedinol).....	2354
LIQUID PEDI-VAXHIB (Merck).....	1853
PEGADEMASE BOVINE Adagen Injection (Enzon).....	990
PEGASPARGASE Oncaspar (Rhône-Poulenc Rorer).....	2600
PEMOLINE Cylert Tablets (Abbott)..... Cylert Chewable Tablets (Abbott).....	303, 416 303, 416
PENBUTOLOL SULFATE Levatol Tablets (Schwarz).....	2908
PENCICLOVIR Denavir Cream (SmithKline Beecham Consumer).....	3010
PENECORT CREAM (Allergan).....	504
PENECORT TOPICAL SOLUTION (Allergan).....	504
◆ PENETREX TABLETS (Rhône-Poulenc Rorer).....	333, 2602
PENICILLAMINE Cuprimine Capsules (Merck)..... Depen Titratable Tablets (Wallace).....	323, 1766 3192
PENICILLIN G BENZATHINE Bicillin C-R 900/300 Injection (Wyeth-Ayerst)..... Bicillin C-R Injection (Wyeth-Ayerst)..... Bicillin L-A Injection (Wyeth-Ayerst)..... Bicillin C-R in Tubex (Wyeth-Ayerst)..... Bicillin C-R 900/300 in Tubex (Wyeth-Ayerst)..... Bicillin L-A in Tubex (Wyeth-Ayerst).....	3276 3276 3278 3396 3396 3396
PENICILLIN G POTASSIUM Pfizerpen for Injection (Pfizer).....	2400

Underline Denotes Generic Name

Italic Page Number Indicates Brief Listing

RX THE PURDUE FREDERICK CO. P. 2561



500 mg



750 mg



750 mg



1000 mg

Trilisate®

(choline magnesium trisalicylate)

RX THE PURDUE FREDERICK CO. P. 2561



500 mg / 5 mL

Trilisate®

(choline magnesium trisalicylate)

RX THE PURDUE FREDERICK CO. P. 2563



400 mg



500 mg



600 mg

Controlled-release tablets

Uniphyl®

(theophylline, anhydrous)

Designed to help you identify drugs, this section contains actual size pills and full color reproduction of products selected for inclusion by participating manufacturers.

Because tablets and capsules are shown in this section, do not infer that these are the only dosage forms available. Where a product name is preceded by the symbol †, refer to the description in the Product Information (White Section) for other forms.

PURDUE PHARMA L.P.

C-II PURDUE PHARMA L.P. P. 2569



10 mg



20 mg



40 mg



80 mg

OxyContin®
(oxycodone HCl controlled-release)

C-II PURDUE PHARMA L.P. P. 2574



Immediate-Release Oral CONCENTRATE Solution 20 mg/1 mL in plastic bottle of 30 mL with child-resistant dropper

OxyFAST™
(oxycodone HCl)

C-II PURDUE PHARMA L.P. P. 2574



OxyR®
(oxycodone HCl immediate-release)

C-V RECKITT & COLMAN P. 2578




0.3 mg per 1 mL ampul

Buprenex® Injectable
(buprenorphine HCl)

RHÔNE-POULENC RORER P. 2589

RHÔNE-POULENC RORER

RX RHÔNE-POULENC RORER P. 2589



60 mg/20 gram inhaler

Azmecort® Inhalation Aerosol
(triamcinolone acetonide)

RX RHÔNE-POULENC RORER P. 2582



1 mL 4 mcg/mL



10 mL 4 mcg/mL

DDAVP® Injection
(desmopressin acetate)

RX RHÔNE-POULENC RORER P. 2583



1 mL 15 mcg/mL



2 mL 15 mcg/mL

DDAVP® Injection 15 mcg/mL
(desmopressin acetate)

RX RHÔNE-POULENC RORER P. 2584



0.1 mg/mL

DDAVP® Nasal Spray
(desmopressin acetate)

RX RHÔNE-POULENC RORER P. 2586



0.1 mg



0.2 mg

DDAVP® Tablets
(desmopressin acetate)

RX RHÔNE-POULENC RORER P. 2587



Gliadel® Wafer
(polifeprosan 20 with carmustine implant)

RX RHÔNE-POULENC RORER P. 2589



Metered dose 800 mcg/inhalation

Intal® Inhaler
(cromolyn sodium inhalation aerosol)

RX RHÔNE-POULENC RORER P. 2590



20 mg/2 mL ampule

Intal® Nebulizer Solution
(cromolyn sodium inhalation solution, USP)

RX RHÔNE-POULENC RORER P. 2591



30 mg



40 mg



60 mg

80 mg

100 mg

Lovenox® Injection
(enoxaparin sodium)

RX RHÔNE-POULENC RORER P. 2596



Metered dose 55 mcg/actuation

Nasacort® Nasal Inhaler
(triamcinolone acetonide)

RX RHÔNE-POULENC RORER P. 2597



Metered dose 55 mcg/actuation

Nasacort® AQ Nasal Spray
(triamcinolone acetonide)

RX RHÔNE-POULENC RORER P. 2599



Metered dose 0.4 mg/actuation

Nitrolingual® Spray
(nitroglycerin lingual aerosol)

RX RHÔNE-POULENC RORER P. 2602



5100* 200 mg



5140* 400 mg

Penetrex™ Tablets
(enoxacin)

RX RHÔNE-POULENC RORER P. 2604



50 mg

Rilutek® Tablets
(riluzole)

RX RHÔNE-POULENC RORER P. 2609



20 mg Concentrate for Infusion



Diluent



80 mg Concentrate for Infusion



Diluent

Taxotere® for Injection Concentrate
(docetaxel)

While every effort has been made to reproduce products faithfully, this section is to be considered a quick reference identification aid. In cases of suspected overdosage, etc., chemical analysis of the product should be done.

neal dialysis is ineffective for theophylline removal; exchange transfusions in neonates have been minimally effective.

DOSAGE AND ADMINISTRATION

Uniphy® 400 or 600 mg Tablets can be taken once a day in the morning or evening. It is recommended that Uniphy be taken with meals. Patients should be advised that if they choose to take Uniphy with food it should be taken consistently with food and if they take it in a fasted condition it should routinely be taken fasted. It is important that the product whenever dosed be dosed consistently with or without food.

Uniphy® Tablets are not to be chewed or crushed. The scored tablet may be split. Infrequently, patients receiving Uniphy® 400 or 600 mg Tablets may pass an intact matrix tablet in the stool or via colostomy. These matrix tablets usually contain little or no residual theophylline.

Stabilized patients, 12 years of age or older, who are taking an immediate-release or controlled-release theophylline product may be transferred to once-daily administration of 400 mg or 600 mg Uniphy® Tablets on a mg-for-mg basis. It must be recognized that the peak and trough serum theophylline levels produced by the once-daily dosing may vary from those produced by the previous product and/or regimen.

General Considerations: The steady-state peak serum theophylline concentration is a function of the dose, the dosing interval, and the rate of theophylline absorption and clearance in the individual patient. Because of marked individual differences in the rate of theophylline clearance, the dose required to achieve a peak serum theophylline concentration in the 10–20 mcg/mL range varies fourfold among otherwise similar patients in the absence of factors known to alter theophylline clearance (e.g., 400–1600 mg/day in adults <60 years old and 10–36 mg/kg/day in children 1–9 years old). For a given population there is no single theophylline dose that will provide both safe and effective serum concentrations for all patients. Administration of the median theophylline dose required to achieve a therapeutic serum theophylline concentration in a given population may result in either sub-therapeutic or potentially toxic serum theophylline concentrations in individual patients. For example, at a dose of 900 mg/d in adults <60 years or 22 mg/kg/d in children 1–9 years, the steady-state peak serum theophylline concentration will be <10 mcg/mL in about 30% of patients, 10–20 mcg/mL in about 50% and 20–30 mcg/mL in about 20% of patients. **The dose of theophylline must be individualized on the basis of peak serum theophylline concentration measurements in order to achieve a dose that will provide maximum potential benefit with minimal risk of adverse effects.**

Transient caffeine-like adverse effects and excessive serum concentrations in slow metabolizers can be avoided in most patients by starting with a sufficiently low dose and slowly increasing the dose, if judged to be clinically indicated, in small increments (See Table V). Dose increases should only be made if the previous dosage is well tolerated and at intervals of no less than 3 days to allow serum theophylline concentrations to reach the new steady-state. Dosage adjustment should be guided by serum theophylline concentration measurement (see PRECAUTIONS, Laboratory Tests and DOSAGE AND ADMINISTRATION, Table VI). Health care providers should instruct patients and care givers to discontinue any dosage that causes adverse effects, to withhold the medication until these symptoms are gone and to then resume therapy at a lower, previously tolerated dosage (see WARNINGS).

If the patient's symptoms are well controlled, there are no apparent adverse effects, and no intervening factors that might alter dosage requirements (see WARNINGS and PRECAUTIONS), serum theophylline concentrations should be monitored at 6 month intervals for rapidly growing children and at yearly intervals for all others. In acutely ill patients, serum theophylline concentrations should be monitored at frequent intervals, e.g., every 24 hours. Theophylline distributes poorly into body fat, therefore, mg/kg dose should be calculated on the basis of ideal body weight.

Table V contains theophylline dosing titration schema recommended for patients in various age groups and clinical circumstances. Table VI contains recommendations for theophylline dosage adjustment based upon serum theophylline concentrations. **Application of these general dosing recommendations to individual patients must take into account the unique clinical characteristics of each patient. In general, these recommendations should serve as the upper limit for dosage adjustments in order to decrease the risk of potentially serious adverse events associated with unexpected large increases in serum theophylline concentration.**

Table V. Dosing initiation and titration (as anhydrous theophylline).*

Titration Step	Children > 45 kg and adults	
	Children < 45 kg	Children > 45 kg and adults
1. Starting Dosage	12–14 mg/kg/day up to a maximum of 300 mg/day admin. QD*	300–400 mg/day† admin. QD*
2. After 3 days, if tolerated, increase dose to:	16 mg/kg/day up to a maximum of 400 mg/day admin. QD*	400–600 mg/day† admin. QD*
3. After 3 more days, if tolerated and if needed increase dose to:	20 mg/kg/day up to a maximum of 600 mg/day admin. QD*	As with all theophylline products, doses greater than 600 mg should be titrated according to blood level (See Table VI)

†If caffeine-like adverse effects occur, then consideration should be given to a lower dose and titrating the dose more slowly (see ADVERSE REACTIONS).

B. Patients With Risk Factors For Impaired Clearance, The Elderly (>60 Years), And Those In Whom It Is Not Feasible To Monitor Serum Theophylline Concentrations:

In children 12–15 years of age, the theophylline dose should not exceed 16 mg/kg/day up to a maximum of 400 mg/day in the presence of risk factors for reduced theophylline clearance (see WARNINGS) or if it is not feasible to monitor serum theophylline concentrations. In adolescents ≥16 years and adults, including the elderly, the theophylline dose should not exceed 400 mg/day in the presence of risk factors for reduced theophylline clearance (see WARNINGS) or if it is not feasible to monitor serum theophylline concentrations.

*Patients with more rapid metabolism clinically identified by higher than average dose requirements, should receive a smaller dose more frequently (every 12 hours) to prevent breakthrough symptoms resulting from low trough concentrations before the next dose.

Table VI. Dosage adjustment guided by serum theophylline concentration.

Peak Serum Concentration	Dosage Adjustment
<9.9 mcg/mL	If symptoms are not controlled and current dosage is tolerated, increase dose about 25%. Recheck serum concentration after three days for further dosage adjustment.
10–14.9 mcg/mL	If symptoms are controlled and current dosage is tolerated, maintain dose and recheck serum concentration at 6–12 month intervals.† If symptoms are not controlled and current dosage is tolerated consider adding additional medication(s) to treatment regimen.
15–19.9 mcg/mL	Consider 10% decrease in dose to provide greater margin of safety even if current dosage is tolerated.†
20–24.9 mcg/mL	Decrease dose by 25% even if no adverse effects are present. Recheck serum concentration after 3 days to guide further dosage adjustment.
25–30 mcg/mL	Skip next dose and decrease subsequent doses at least 25% even if no adverse effects are present. Recheck serum concentration after 3 days to guide further dosage adjustment. If symptomatic, consider whether overdose treatment is indicated (see recommendations for chronic overdosage).
>30 mcg/mL	Treat overdose as indicated (see recommendations for chronic overdosage). If theophylline is subsequently resumed, decrease dose by at least 50% and recheck serum concentration after 3 days to guide further dosage adjustment.

†Dose reduction and/or serum theophylline concentration measurement is indicated whenever adverse effects are present, physiologic abnormalities that can reduce theophylline clearance occur (e.g., sustained fever), or a drug that interacts with theophylline is added or discontinued (see WARNINGS).

HOW SUPPLIED

Uniphy® (theophylline, anhydrous) 400 mg Controlled-Release Tablets are supplied in white-opaque plastic bottles containing 100 tablets (NDC 0034-7004-80) or 500 tablets (NDC 0034-7004-70).

Each round, white, scored 400 mg tablet bears the symbol PF on one side and is marked U400 on the other side.

Uniphy® (theophylline, anhydrous) 600 mg Controlled-Release Tablets are supplied in white-opaque plastic bottles containing 100 tablets (NDC 0034-7006-80).

Each rectangular, concave, white 600 mg scored tablet bears the symbol PF on one side and is marked U600 on the other side.

Store at controlled room temperature 15°–30°C (59°–86°F). Dispense in tight, light-resistant container.

CAUTION: Federal law prohibits dispensing without prescription.

The Purdue Frederick Company
 Norwalk, CT 06850-3590
 Copyright ©1996 The Purdue Frederick Company
 U.S. Patent Numbers 4,235,870 and 4,366,810
 June 12, 1996 R1374

Shown in Product Identification Guide, page 333

EDUCATIONAL MATERIAL

Laxative Protocol Sheets (PS77) 1 page (pad of 25)
 Available to physicians, nurses and pharmacists

Purdue Pharma L.P.
 100 CONNECTICUT AVENUE
 NORWALK, CT 06850-3590

DHCplus® Capsules

MS Contin® Tablets—see listing under The Purdue Frederick Company, page 2556

MSIR® Capsules—see listing under The Purdue Frederick Company, page 2559

MSIR® Tablets—see listing under The Purdue Frederick Company, page 2559

MSIR® Liquid—see listing under The Purdue Frederick Company, page 2559


OXYCONTIN® (OXYCODONE HCL CONTROLLED-RELEASE) TABLETS

Warning—May be habit forming.
 10mg 20mg 40mg 80mg*

*80 mg For use in opioid tolerant patients only.

DESCRIPTION

OxyContin® (oxycodone hydrochloride controlled-release) tablets are an opioid analgesic supplied in 10 mg, 20 mg, 40 mg, and 80 mg tablet strengths for oral administration. The tablet strengths describe the amount of oxycodone per tablet as the hydrochloride salt. The structural formula for oxycodone hydrochloride is as follows:



C₁₈H₂₁NO₄•HCl

MW 351.83

The chemical formula is 4, 5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride.

Oxycodone is a white, odorless crystalline powder derived from the opium alkaloid, thebaine. Oxycodone hydrochloride dissolves in water (1 g in 6 to 7 mL). It is slightly soluble in alcohol (octanol water partition coefficient 0.7). The tablets contain the following inactive ingredients: ammonio

Continued on next page

Consult 1999 PDR® supplements and future editions for revisions

OxyContin—Cont.

methacrylate copolymer, hydroxypropyl methylcellulose, lactose, magnesium stearate, povidone, red iron oxide (20 mg strength tablet only), stearyl alcohol, talc, titanium dioxide, triacetin, yellow iron oxide (40 mg strength tablet only), yellow iron oxide with FD&C blue No. 2 (80 mg strength tablet only), and other ingredients.

OxyContin® 80 mg Tablets ARE FOR USE IN OPIOID TOLERANT PATIENTS ONLY.

CLINICAL PHARMACOLOGY

Central Nervous System

Oxycodone is a pure agonist opioid whose principal therapeutic action is analgesia. Other therapeutic effects of oxycodone include anxiolysis, euphoria and feelings of relaxation. Like all pure opioid agonists, there is no ceiling effect to analgesia, such as is seen with partial agonists or non-opioid analgesics.

The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and play a role in the analgesic effects of this drug.

Oxycodone produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves both a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation.

Oxycodone depresses the cough reflex by direct effect on the cough center in the medulla. Antitussive effects may occur with doses lower than those usually required for analgesia. Oxycodone causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic. Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations.

Gastrointestinal Tract and Other Smooth Muscle

Oxycodone causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid-induced effects may include a reduction in gastric, biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase.

Cardiovascular System

Oxycodone may produce release of histamine with or without associated peripheral vasodilation. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.

Concentration—Efficacy Relationships (Pharmacodynamics)

Studies in normal volunteers and patients reveal predictable relationships between oxycodone dosage and plasma oxycodone concentrations, as well as between concentration and certain expected opioid effects. In normal volunteers these include pupillary constriction, sedation and overall "drug effect" and in patients, analgesia and feelings of "relaxation." In non-tolerant patients, analgesia is not usually seen at a plasma oxycodone concentration of less than 5–10 ng/mL.

As with all opioids, the minimum effective plasma concentration for analgesia will vary widely among patients, especially among patients who have been previously treated with potent agonist opioids. As a result, patients need to be treated with individualized titration of dosage to the desired effect. The minimum effective analgesic concentration of oxycodone for any individual patient may increase with repeated dosing due to an increase in pain and/or the development of tolerance.

Concentration—Adverse Experience Relationships

OxyContin tablets are associated with typical opioid-related adverse experiences similar to those seen with immediate-release oxycodone and all opioids. There is a general relationship between increasing oxycodone plasma concentration and increasing frequency of dose-related opioid adverse experiences such as nausea, vomiting, CNS effects and respiratory depression. In opioid-tolerant patients, the situation is altered by the development of tolerance to opioid-related side effects, and the relationship is poorly understood.

As with all opioids, the dose must be individualized (see DOSAGE AND ADMINISTRATION), because the effective analgesic dose for some patients will be too high to be tolerated by other patients.

PHARMACOKINETICS AND METABOLISM


The activity of OxyContin® (oxycodone hydrochloride controlled-release) tablets is primarily due to the parent drug oxycodone. OxyContin tablets are designed to provide controlled delivery of oxycodone over 12 hours. Oxycodone is well absorbed from OxyContin tablets with an oral bioavailability of from 60% to 87%. The relative oral bioavailability

of OxyContin to immediate-release oral dosage forms is 100%. Upon repeated dosing in normal volunteers, steady-state levels were achieved within 24–36 hours. Dose proportionality has been established for the 10 mg, 20 mg, 40 mg, and 80 mg tablet strengths for both peak plasma levels (C_{max}) and extent of absorption (AUC). Oxycodone is extensively metabolized and eliminated primarily in the urine as both conjugated and unconjugated metabolites. The apparent elimination half-life of oxycodone following the administration of OxyContin was 4.5 hours compared to 3.2 hours for immediate-release oxycodone.

Absorption

About 60% to 87% of an oral dose of oxycodone reaches the central compartment in comparison to a parenteral dose. This high oral bioavailability is due to low pre-systemic and/or first-pass metabolism. In normal volunteers the $t_{1/2}$ of absorption is 0.4 hours for immediate-release oral oxycodone. In contrast, OxyContin tablets exhibit a biphasic absorption pattern with two apparent absorption half-times of 0.6 and 6.9 hours, which describes the initial release of oxycodone from the tablet followed by a prolonged release.

Plasma Oxycodone By Time



Dose proportionality has been established for the 10 mg, 20 mg, 40 mg, and 80 mg tablet strengths for both peak plasma concentrations (C_{max}) and extent of absorption (AUC) (see Table 1 below). Given the short half-life of elimination of oxycodone from OxyContin, steady-state plasma concentrations of oxycodone are achieved within 24–36 hours of initiation of dosing with OxyContin tablets. In a study comparing 10 mg of OxyContin every 12 hours to 5 mg of immediate-release oxycodone every 6 hours the two treatments were found to be equivalent for AUC and C_{max} , and similar for C_{min} (trough) concentrations. There was less fluctuation in plasma concentrations for the OxyContin tablets than for the immediate-release formulation. [See table 1 below]

Food Effects

In contrast to immediate-release formulations, food has no significant effect on the absorption of oxycodone from OxyContin. Oxycodone release from OxyContin tablets is pH independent.

Distribution

Following intravenous administration, the volume of distribution (V_{ss}) for oxycodone was 2.6L/kg. Oxycodone binding to plasma protein at 37°C and a pH of 7.4 was about 45%. Once absorbed, oxycodone is distributed to skeletal muscle, liver, intestinal tract, lungs, spleen and brain. Oxycodone has been found in breast milk (see PRECAUTIONS).

Metabolism

Oxycodone hydrochloride is extensively metabolized to noroxycodone, oxycodone, and their glucuronides. The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone. Noroxycodone is reported to be a considerably weaker analgesic than

oxycodone. Oxycodone, although possessing analgesic activity, is present in the plasma only in low concentrations. The correlation between oxycodone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations. The analgesic activity profile of other metabolites is not known at present.

The formation of oxycodone, but not noroxycodone, is mediated by CYP2D6 and as such its formation can, in theory, be affected by other drugs (see Drug-Drug Interactions).

Excretion

Oxycodone and its metabolites are excreted primarily via the kidney. The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxycodone 0%; conjugated oxycodone up to 14%; both free and conjugated noroxycodone have been found in the urine but not quantified. The total plasma clearance was 0.8 L/min for adults.

Special Populations

Elderly

The plasma concentrations of oxycodone are only nominally affected by age, being 15% greater in elderly as compared to young subjects. There were no differences in adverse event reporting between young and elderly subjects.

Gender

Female subjects have, on average, plasma oxycodone concentrations up to 25% higher than males on a body weight adjusted basis. The reason for this difference is unknown.

Renal Impairment

Preliminary data from a study involving patients with mild to severe renal dysfunction (creatinine clearance <60 mL/min) show peak plasma oxycodone and noroxycodone concentrations 50% and 20% higher, respectively, and AUC values for oxycodone, noroxycodone and oxycodone 60%, 50% and 40% higher than normal subjects, respectively. This is accompanied by an increase in sedation but not by differences in respiratory rate, pupillary constriction, or several other measures of drug effect. There was an increase in $t_{1/2}$ of elimination for oxycodone of only 1 hour (see PRECAUTIONS).

Hepatic Impairment

Preliminary data from a study involving patients with mild to moderate hepatic dysfunction show peak plasma oxycodone and noroxycodone concentrations 50% and 20% higher, respectively, than normal subjects. AUC values are 95% and 65% higher, respectively. Oxycodone peak plasma concentrations and AUC values are lower by 30% and 40%. These differences are accompanied by increases in some, but not other, drug effects. The $t_{1/2}$ elimination for oxycodone increased by 2.3 hours (see PRECAUTIONS).

Rectal Administration

Rectal administration of OxyContin tablets is not recommended. Preliminary data from a study involving 21 normal volunteers, show OxyContin tablets administered per rectum resulted in an AUC 39% greater and a C_{max} 9% higher than tablets administered by mouth (see PRECAUTIONS).

Drug-Drug Interactions (see PRECAUTIONS)

Oxycodone is metabolized in part via CYP2D6 to oxycodone which represents less than 15% of the total administered dose. This route of elimination can be blocked by a variety of drugs (e.g., certain cardiovascular drugs and antidepressants). Patients receiving such drugs concomitantly with OxyContin do not appear to present different therapeutic profiles than other patients.

CLINICAL TRIALS

OxyContin® (oxycodone hydrochloride controlled-release) tablets were evaluated in studies involving 713 patients with either cancer or non-cancer pain. All patients receiving OxyContin were dosed q12h. Efficacy comparable to other forms of oral oxycodone was demonstrated in clinical studies using pharmacokinetic, pharmacodynamic and efficacy outcomes. The outcome of these trials indicated: (1) a positive relationship between dose and plasma oxycodone concentration, (2) a positive relationship between plasma oxy-

Table 1

Mean [% coefficient variation]

Regimen/Dosage Form	AUC (ng·hr/mL)†	C_{max} (ng/mL)	T_{max} (hrs)	Trough Conc. (ng/mL)
Single Dose				
10 mg OxyContin	100.7 [26.6]	10.6 [20.1]	2.7 [44.1]	n.a.
20 mg OxyContin	207.5 [35.9]	21.4 [36.6]	3.2 [57.9]	n.a.
40 mg OxyContin	423.1 [33.3]	39.3 [34.0]	3.1 [77.4]	n.a.
80 mg OxyContin*	1085.5 [32.3]	98.5 [32.1]	2.1 [52.3]	n.a.
Multiple Dose				
10 mg OxyContin Tablets q12h	103.6 [38.6]	15.1 [31.0]	3.2 [69.5]	7.2 [48.1]
5 mg immediate-release q6h	99.0 [36.2]	15.5 [28.8]	1.6 [49.7]	7.4 [50.9]

† for single-dose AUC=AUC_{0-inf}; for multiple-dose AUC=AUC_{0-T}

* data obtained while volunteers received naloxone which can enhance absorption.

codone concentration and analgesia, and (3) an observed peak to trough variation in plasma concentration with OxyContin lying within the observed range established with qid dosing of immediate-release oxycodone in clinical populations at the same total daily dose.

In clinical trials, OxyContin tablets were substituted for a wide variety of analgesics, including acetaminophen (APAP), aspirin (ASA), other non-steroidal anti-inflammatory drugs (NSAIDs), opioid combination products and single-entity opioids, primarily morphine. In cancer patients receiving adequate opioid therapy at baseline, pain intensity scores and acceptability of therapy remained unchanged by transfer to OxyContin. For non-cancer pain patients who had moderate to severe pain at baseline on prn opioid therapy, pain control and acceptability of therapy improved with the introduction of fixed-interval therapy with OxyContin.

Use in Cancer Pain

OxyContin was studied in three double-blind, controlled clinical trials involving 341 cancer patients and several open-label trials with therapy durations of over 10 months. Two, double-blind, controlled clinical studies indicated that OxyContin dosed q12h produced analgesic efficacy equivalent to immediate-release oxycodone dosed qid at the same total daily dose. Peak and trough plasma concentrations attained were similar to those attained with immediate-release oxycodone at equivalent total daily doses. With titration to analgesic effect and proper use of rescue medication, nearly every patient achieved adequate pain control with OxyContin.

In the third study, a double-blind, active-controlled, crossover trial, OxyContin dosed q12h was shown to be equivalent in efficacy and safety to immediate-release oxycodone dosed qid at the same total daily dose. Patients were able to be titrated to an acceptable analgesic effect with either OxyContin or immediate-release oxycodone with both treatments providing stable pain control within 2 days in most patients.

In patients with cancer pain, the total daily OxyContin doses tested ranged from 20 mg to 640 mg per day. The average total daily dose was approximately 105 mg per day.

Studies in Non-Cancer Pain

A double-blind, placebo-controlled, fixed-dose, parallel group study was conducted in 133 patients with moderate to severe osteoarthritis pain, who were judged as having inadequate pain control with prn opioids and maximal non-steroidal anti-inflammatory therapy. In this study, 20 mg OxyContin q12h significantly decreased pain and improved quality of life, mood and sleep, relative to placebo. Both dose-concentration and concentration-effect relationships were noted with a minimum effective plasma oxycodone concentration of approximately 5–10 ng/mL.

In a double-blind, active-controlled, crossover study involving 57 patients with low-back pain inadequately controlled with prn opioids and non-opioid therapy, OxyContin administered q12h provided analgesia equivalent to immediate-release oxycodone administered qid. Patients could be titrated to an acceptable analgesic effect with either OxyContin or immediate-release forms of oxycodone.

Single-Dose Comparison with Standard Therapy

A single-dose, double-blind, placebo-controlled, post-operative study of 182 patients was conducted utilizing graded doses of OxyContin (10, 20 and 30 mg). Twenty and 30 mg of OxyContin gave equivalent peak analgesic effect compared to two oxycodone 5 mg/acetaminophen 325 mg tablets and to 15 mg immediate-release oxycodone, while the 10 mg dose of OxyContin was intermediate between both the immediate-release and combination products and placebo. The onset of analgesic action with OxyContin occurred within 1 hour in most patients following oral administration.

OxyContin is not recommended pre-operatively (preemptive analgesia) or for the management of pain in the immediate post-operative period (the first 12 to 24 hours following surgery) because the safety or appropriateness of fixed-dose, long-acting opioids in this setting has not been established.

Other Clinical Trials

In open-label trials involving approximately 200 patients with cancer-related and non-cancer pain, dosed according to the package insert recommendations, appropriate analgesic effectiveness was noted without regard to age, gender, race, or disease state. There were no unusual drug interactions observed in patients receiving a wide range of medications common in these populations.

For opioid-naïve patients, the average total daily dose of OxyContin was approximately 40 mg per day. There was no evidence of oxycodone and metabolite accumulation during 8 months of therapy. For cancer pain patients the average total daily dose was 105 mg (range 20 to 720 mg) per day. There was a significant decrease in acute opioid-related side effects, except for constipation, during the first several weeks of therapy. Development of significant tolerance to analgesia was uncommon.

A cohort of patients have been treated with OxyContin 80 mg tablets. There were no differences in the efficacy or safety profiles than seen with the other tablet strengths.

INDICATIONS AND USAGE

OxyContin® tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain where use of an opioid analgesic is appropriate for more than a few days. (See: CLINICAL PHARMACOLOGY; CLINICAL TRIALS).

CONTRAINDICATIONS

OxyContin® is contraindicated in patients with known hypersensitivity to oxycodone, or in any situation where opioids are contraindicated. This includes patients with significant respiratory depression (in unmonitored settings or the absence of resuscitative equipment), and patients with acute or severe bronchial asthma or hypercarbia. OxyContin is contraindicated in any patient who has or is suspected of having paralytic ileus.

WARNINGS

OxyContin® (oxycodone hydrochloride controlled-release) TABLETS ARE TO BE SWALLOWED WHOLE, AND ARE NOT TO BE BROKEN, CHEWED OR CRUSHED. TAKING BROKEN, CHEWED OR CRUSHED OxyContin TABLETS COULD LEAD TO THE RAPID RELEASE AND ABSORPTION OF A POTENTIALLY TOXIC DOSE OF OXYCODONE.

Respiratory Depression

Respiratory depression is the chief hazard from all opioid agonist preparations. Respiratory depression occurs most frequently in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other agents that depress respiration.

Oxycodone should be used with extreme caution in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and in patients having a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression. In such patients, even usual therapeutic doses of oxycodone may decrease respiratory drive to the point of apnea. In these patients alternative non-opioid analgesics should be considered, and opioids should be employed only under careful medical supervision at the lowest effective dose.

Head Injury

The respiratory depressant effects of opioids include carbon dioxide retention and secondary elevation of cerebrospinal fluid pressure, and may be markedly exaggerated in the presence of head injury, intracranial lesions, or other sources of preexisting increased intracranial pressure. Oxycodone produces effects on pupillary response and consciousness which may obscure neurologic signs of further increases in intracranial pressure in patients with head injuries.

Hypotensive Effect

OxyContin®, like all opioid analgesics, may cause severe hypotension in an individual whose ability to maintain blood pressure has been compromised by a depleted blood volume, or after concurrent administration with drugs such as phenothiazines or other agents which compromise vasomotor tone. OxyContin may produce orthostatic hypotension in ambulatory patients. OxyContin, like all opioid analgesics, should be administered with caution to patients in circulatory shock, since vasodilation produced by the drug may further reduce cardiac output and blood pressure.

PRECAUTIONS

Special precautions regarding OxyContin® 80 mg Tablets
OxyContin® 80 mg Tablets are for use only in opioid tolerant patients requiring daily oxycodone equivalent dosages of 160 mg or more. Care should be taken in the prescription of this tablet strength. Patients should be instructed against use by individuals other than the patient for whom it was prescribed, as such inappropriate use may have severe medical consequences.

General

OxyContin® (oxycodone hydrochloride controlled-release) tablets are intended for use in patients who require oral pain therapy with an opioid agonist of more than a few days duration. As with any opioid analgesic, it is critical to adjust the dosing regimen individually for each patient (see DOSAGE AND ADMINISTRATION).

Selection of patients for treatment with OxyContin should be governed by the same principles that apply to the use of similar controlled-release opioid analgesics (see INDICATIONS AND USAGE). Opioid analgesics given on a fixed-dosage schedule have a narrow therapeutic index in certain patient populations, especially when combined with other drugs, and should be reserved for cases where the benefits of opioid analgesia outweigh the known risks of respiratory depression, altered mental state, and postural hypotension. Physicians should individualize treatment in every case, using non-opioid analgesics, prn opioids and/or combination products, and chronic opioid therapy with drugs such as OxyContin in a progressive plan of pain management such as outlined by the World Health Organization, the Agency for Health Care Policy and Research, and the American Pain Society.

Use of OxyContin is associated with increased potential risks and should be used only with caution in the following

conditions: acute alcoholism; adrenocortical insufficiency (e.g., Addison's disease); CNS depression or coma; delirium tremens; debilitated patients; kyphoscoliosis associated with respiratory depression; myxedema or hypothyroidism; prostatic hypertrophy or urethral stricture; severe impairment of hepatic, pulmonary or renal function; and toxic psychosis.

The administration of oxycodone, like all opioid analgesics, may obscure the diagnosis or clinical course in patients with acute abdominal conditions. Oxycodone may aggravate convulsions in patients with convulsive disorders, and all opioids may induce or aggravate seizures in some clinical settings.

Interactions with other CNS Depressants

OxyContin, like all opioid analgesics, should be used with caution and started in a reduced dosage ($1/3$ to $1/2$ of the usual dosage) in patients who are concurrently receiving other central nervous system depressants including sedatives or hypnotics, general anesthetics, phenothiazines, other tranquilizers and alcohol. Interactive effects resulting in respiratory depression, hypotension, profound sedation or coma may result if these drugs are taken in combination with the usual doses of OxyContin.

Interactions with Mixed Agonist/Antagonist Opioid Analgesics

Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) should be administered with caution to a patient who has received or is receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone. In this situation, mixed agonist/antagonist analgesics may reduce the analgesic effect of oxycodone and/or may precipitate withdrawal symptoms in these patients.

Ambulatory Surgery

OxyContin is not recommended pre-operatively (preemptive analgesia) or for the management of pain in the immediate post-operative period (the first 12 to 24 hours following surgery) for patients not previously taking the drug, because its safety in this setting has not been established.

Patients who are already receiving OxyContin tablets as part of ongoing analgesic therapy may be safely continued on the drug if appropriate dosage adjustments are made considering the procedure, other drugs given and the temporary changes in physiology caused by the surgical intervention (see PRECAUTIONS: Drug-Drug Interactions, and DOSAGE AND ADMINISTRATION).

Post-Operative Use

Morphine and other opioids have been shown to decrease bowel motility. Ileus is a common post-operative complication, especially after intra-abdominal surgery with opioid analgesia. Caution should be taken to monitor for decreased bowel motility in post-operative patients receiving opioids. Standard supportive therapy should be implemented.

Use in Pancreatic/Biliary Tract Disease

Oxycodone may cause spasm of the sphincter of Oddi and should be used with caution in patients with biliary tract disease, including acute pancreatitis. Opioids like oxycodone may cause increases in the serum amylase level.

Tolerance and Physical Dependence

Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Physical dependence is the occurrence of withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical dependence and tolerance are not unusual during chronic opioid therapy.

Significant tolerance should not occur in most of the patients treated with the lowest doses of oxycodone. It should be expected, however, that a fraction of cancer patients will develop some degree of tolerance and require progressively higher dosages of OxyContin to maintain pain control during chronic treatment. Regardless of whether this occurs as a result of increased pain secondary to disease progression or pharmacological tolerance, dosages can usually be increased safely by adjusting the patient's dose to maintain an acceptable balance between pain relief and side effects. The dosage should be selected according to the patient's individual analgesic response and ability to tolerate side effects. Tolerance to the analgesic effect of opioids is usually paralleled by tolerance to side effects, except for constipation.

Physical dependence results in withdrawal symptoms in patients who abruptly discontinue the drug or may be precipitated through the administration of drugs with opioid antagonist activity (see OVERDOSAGE). If OxyContin is abruptly discontinued in a physically dependent patient, an abstinence syndrome may occur. This is characterized by some or all of the following: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia and mydriasis. Other symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate or heart rate.

If signs and symptoms of withdrawal occur, patients should be treated by reinstatement of opioid therapy followed by a

Continued on next page

Consult 1999 PDR® supplements and future editions for revisions

OxyContin—Cont.

gradual, tapered dose reduction of OxyContin combined with symptomatic support (see DOSAGE AND ADMINISTRATION: Cessation of Therapy).

Information for Patients/Caregivers

If clinically advisable, patients receiving OxyContin (oxycodone hydrochloride controlled-release) tablets or their caregivers should be given the following information by the physician, nurse, pharmacist or caregiver:

1. Patients should be advised that OxyContin tablets were designed to work properly only if swallowed whole. They may release all their contents at once if broken, chewed or crushed, resulting in a risk of overdose.
2. Patients should be advised to report episodes of breakthrough pain and adverse experiences occurring during therapy. Individualization of dosage is essential to make optimal use of this medication.
3. Patients should be advised not to adjust the dose of OxyContin without consulting the prescribing professional.
4. Patients should be advised that OxyContin may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating heavy machinery).
5. Patients should not combine OxyContin with alcohol or other central nervous system depressants (sleep aids, tranquilizers) except by the orders of the prescribing physician, because additive effects may occur.
6. Women of childbearing potential who become, or are planning to become, pregnant should be advised to consult their physician regarding the effects of analgesics and other drug use during pregnancy on themselves and their unborn child.
7. Patients should be advised that OxyContin is a potential drug of abuse. They should protect it from theft, and it should never be given to anyone other than the individual for whom it was prescribed.
8. Patients should be advised that they may pass empty matrix "ghosts" (tablets) via colostomy or in the stool, and that this is of no concern since the active medication has already been absorbed.
9. Patients should be advised that if they have been receiving treatment with OxyContin for more than a few weeks and cessation of therapy is indicated, it may be appropriate to taper the OxyContin dose, rather than abruptly discontinue it, due to the risk of precipitating withdrawal symptoms. Their physician can provide a dose schedule to accomplish a gradual discontinuation of the medication.

Laboratory Monitoring

Due to the broad range of plasma concentrations seen in clinical populations, the varying degrees of pain, and the development of tolerance, plasma oxycodone measurements are usually not helpful in clinical management. Plasma concentrations of the active drug substance may be of value in selected, unusual or complex cases.

Interactions with Alcohol and Drugs of Abuse

Oxycodone may be expected to have additive effects when used in conjunction with alcohol, other opioids or illicit drugs which cause central nervous system depression.

Use in Drug and Alcohol Addiction

OxyContin is an opioid with no approved use in the management of addictive disorders. Its proper usage in individuals with drug or alcohol dependence, either active or in remission, is for the management of pain requiring opioid analgesia.

Drug-Drug Interactions

Opioid analgesics, including OxyContin, may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. Oxycodone is metabolized in part to oxymorphone via CYP2D6. While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs and antidepressants), such blockade has not yet been shown to be of clinical significance with this agent. Clinicians should be aware of this possible interaction, however.

Use with CNS Depressants

OxyContin, like all opioid analgesics, should be started at $\frac{1}{3}$ to $\frac{1}{2}$ of the usual dosage in patients who are concurrently receiving other central nervous system depressants including sedatives or hypnotics, general anesthetics, phenothiazines, centrally acting anti-emetics, tranquilizers and alcohol because respiratory depression, hypotension and profound sedation or coma may result. No specific interaction between oxycodone and monoamine oxidase inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate.

Mutagenicity/Carcinogenicity

Oxycodone was not mutagenic in the following assays: Ames Salmonella and E. Coli test with and without metabolic activation at doses of up to 5000 μ g, chromosomal aberration test in human lymphocytes (in the absence of metabolic activation and with activation after 48 hours of exposure) at doses of up to 1500 μ g/ml, and in the *in vivo* bone marrow micronucleus assay in mice (at plasma levels of up to

48 μ g/ml). Mutagenic results occurred in the presence of metabolic activation in the human chromosomal aberration test (at greater than or equal to 1250 μ g/ml) at 24 but not 48 hours of exposure and in the mouse lymphoma assay at doses of 50 μ g/ml or greater with metabolic activation and at 400 μ g/ml or greater without metabolic activation. The data from these tests indicate that the genotoxic risk to humans may be considered low.

Studies of oxycodone in animals to evaluate its carcinogenic potential have not been conducted owing to the length of clinical experience with the drug substance.

Pregnancy

Teratogenic Effects—Category B: Reproduction studies have been performed in rats and rabbits by oral administration at doses up to 8 mg/kg (48 mg/m²) and 125 mg/kg (1375 mg/m²), respectively. These doses are 4 and 60 times a human dose of 120 mg/day (74 mg/m²), based on a 60 kg adult (0.7 and 19 times this human dose based upon mg/m²). The results did not reveal evidence of harm to the fetus due to oxycodone. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nonteratogenic Effects—Neonates whose mothers have been taking oxycodone chronically may exhibit respiratory depression and/or withdrawal symptoms, either at birth and/or in the nursery.

Labor and Delivery

OxyContin is not recommended for use in women during and immediately prior to labor and delivery because oral opioids may cause respiratory depression in the newborn.

Nursing Mothers

Low concentrations of oxycodone have been detected in breast milk. Withdrawal symptoms can occur in breast-feeding infants when maternal administration of an opioid analgesic is stopped. Ordinarily, nursing should not be undertaken while a patient is receiving OxyContin since oxycodone may be excreted in the milk.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of 18 have not been established with this dosage form of oxycodone. However, oxycodone has been used extensively in the pediatric population in other dosage forms, as have the excipients used in this formulation. No specific increased risk is expected from the use of this form of oxycodone in pediatric patients old enough to safely take tablets if dosing is adjusted for the patient's weight (see DOSAGE AND ADMINISTRATION). It must be remembered that OxyContin tablets cannot be crushed or divided for administration.

Geriatric Use

In controlled pharmacokinetic studies in elderly subjects (greater than 65 years) the clearance of oxycodone appeared to be slightly reduced. Compared to young adults, the plasma concentrations of oxycodone were increased approximately 15%. In clinical trials with appropriate initiation of therapy and dose titration, no untoward or unexpected side effects were seen based on age, and the usual doses and dosing intervals are appropriate for the geriatric patient. As with all opioids, the starting dose should be reduced to $\frac{1}{3}$ to $\frac{1}{2}$ of the usual dosage in debilitated, non-tolerant patients.

Hepatic Impairment

A study of OxyContin in patients with hepatic impairment indicates greater plasma concentrations than those with normal function. The initiation of therapy at $\frac{1}{3}$ to $\frac{1}{2}$ the usual doses and careful dose titration is warranted.

Renal Impairment

In patients with renal impairment, as evidenced by decreased creatinine clearance (<60 mL/min.), the concentrations of oxycodone in the plasma are approximately 50% higher than in subjects with normal renal function. Dose initiation should follow a conservative approach. Dosages should be adjusted according to the clinical situation.

Gender Differences

In pharmacokinetic studies, opioid-naïve females demonstrate up to 25% higher average plasma concentrations and greater frequency of typical opioid adverse events than males, even after adjustment for body weight. The clinical relevance of a difference of this magnitude is low for a drug intended for chronic usage at individualized dosages, and there was no male/female difference detected for efficacy or adverse events in clinical trials.

Rectal Administration

OxyContin® Tablets are not recommended for administration per rectum. A study in normal volunteers showed a significantly greater AUC and higher C_{max} during this route of administration (see PHARMACOKINETICS AND METABOLISM).

ADVERSE REACTIONS

Serious adverse reactions which may be associated with OxyContin® (oxycodone hydrochloride controlled-release) tablet therapy in clinical use are those observed with other

opioid analgesics, including: respiratory depression, apnea, respiratory arrest, and (to an even lesser degree) circulatory depression, hypotension or shock (see OVERDOSE).

The non-serious adverse events seen on initiation of therapy with OxyContin are typical opioid side effects. These events are dose-dependent, and their frequency depends upon the dose, the clinical setting, the patient's level of opioid tolerance, and host factors specific to the individual. They should be expected and managed as a part of opioid analgesia. The most frequent (>5%) include constipation, nausea, somnolence, dizziness, vomiting, pruritus, headache, dry mouth, sweating and asthenia.

In many cases the frequency of these events during initiation of therapy may be minimized by careful individualization of starting dosage, slow titration, and the avoidance of large swings in the plasma concentrations of the opioid. Many of these adverse events will cease or decrease in intensity as OxyContin therapy is continued and some degree of tolerance is developed.

In clinical trials comparing OxyContin with immediate-release oxycodone and placebo, the most common adverse events (>5%) reported by patients (pts) at least once during therapy were:

Table 2

	OxyContin (n=227) #Pts (%)	Immediate- Release (n=225) #Pts (%)	Placebo (n=45) #Pts (%)
Constipation	52 (23)	58 (26)	3 (7)
Nausea	52 (23)	60 (27)	5 (11)
Somnolence	52 (23)	55 (24)	2 (4)
Dizziness	29 (13)	35 (16)	4 (9)
Pruritus	29 (13)	28 (12)	1 (2)
Vomiting	27 (12)	31 (14)	3 (7)
Headache	17 (7)	19 (8)	3 (7)
Dry Mouth	13 (6)	15 (7)	1 (2)
Asthenia	13 (6)	16 (7)	—
Sweating	12 (5)	13 (6)	1 (2)

The following adverse experiences were reported in OxyContin treated patients with an incidence between 1% and 5%. In descending order of frequency they were: anorexia, nervousness, insomnia, fever, confusion, diarrhea, abdominal pain, dyspepsia, rash, anxiety, euphoria, dyspnea, postural hypotension, chills, twitching, gastritis, abnormal dreams, thought abnormalities, and hiccups.

The following adverse reactions occurred in less than 1% of patients involved in clinical trials:

General: accidental injury, chest pain, facial edema, malaise, neck pain, pain

Cardiovascular: migraine, syncope, vasodilation, ST depression

Digestive: dysphagia, eructation, flatulence, gastrointestinal disorder, increased appetite, nausea and vomiting, stomatitis, ileus

Hemic and Lymphatic: lymphadenopathy

Metabolic and Nutritional: dehydration, edema, hyponatremia, peripheral edema, syndrome of inappropriate antidiuretic hormone secretion, thirst

Nervous: abnormal gait, agitation, amnesia, depersonalization, depression, emotional lability, hallucination, hyperkinesia, hypesthesia, hypotonia, malaise, paresthesia, seizures, speech disorder, stupor, tinnitus, tremor, vertigo, withdrawal syndrome with or without seizures

Respiratory: cough increased, pharyngitis, voice alteration

Skin: dry skin, exfoliative dermatitis, urticaria

Special Senses: abnormal vision, taste perversion

Urogenital: dysuria, hematuria, impotence, polyuria, urinary retention, urination impaired

DRUG ABUSE AND DEPENDENCE (Addiction)

OxyContin® is a mu-agonist opioid with an abuse liability similar to morphine and is a Schedule II controlled substance. Oxycodone products are common targets for both drug abusers and drug addicts. Delayed absorption, as provided by OxyContin tablets, is believed to reduce the abuse liability of a drug.

Drug addiction (drug dependence, psychological dependence) is characterized by a preoccupation with the procurement, hoarding, and abuse of drugs for non-medical purposes. Drug dependence is treatable, utilizing a multi-disciplinary approach, but relapse is common. Iatrogenic "addiction" to opioids legitimately used in the management of pain is very rare. "Drug seeking" behavior is very common to addicts. Tolerance and physical dependence in pain patients are not signs of psychological dependence. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control. Most chronic pain patients limit their intake of opioids to achieve a balance between the benefits of the drug and dose-limiting side effects.

Physicians should be aware that psychological dependence may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true psycholog-

ical dependence and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances.

OxyContin consists of a dual-polymer matrix, intended for oral use only. Parenteral venous injection of the tablet constituents, especially talc, can be expected to result in local tissue necrosis and pulmonary granulomas.

OVERDOSAGE

Acute overdosage with oxycodone can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death.

In the treatment of oxycodone overdosage, primary attention should be given to the re-establishment of a patent airway and institution of assisted or controlled ventilation. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation.

The pure opioid antagonists such as naloxone or nalmefene are specific antidotes against respiratory depression from opioid overdose. Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to oxycodone overdose. They should be administered cautiously to persons who are known, or suspected to be, physically dependent on any opioid agonist including OxyContin®. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute abstinence syndrome. The severity of the withdrawal syndrome produced will depend on the degree of physical dependence and the dose of the antagonist administered. Please see the prescribing information for the specific opioid antagonist for details of their proper use.

DOSAGE AND ADMINISTRATION

General Principles

OxyContin® (oxycodone hydrochloride controlled-release) TABLETS ARE TO BE SWALLOWED WHOLE, AND ARE NOT TO BE BROKEN, CHEWED OR CRUSHED. TAKING BROKEN, CHEWED OR CRUSHED OxyContin TABLETS COULD LEAD TO THE RAPID RELEASE AND ABSORPTION OF A POTENTIALLY TOXIC DOSE OF OXYCODONE.

In treating pain it is vital to assess the patient regularly and systematically. Therapy should also be regularly reviewed and adjusted based upon the patient's own reports of pain and side effects and the health professional's clinical judgment.

OxyContin is intended for the management of moderate to severe pain in patients who require treatment with an oral opioid analgesic for more than a few days. The controlled-release nature of the formulation allows it to be effectively administered every 12 hours. (See CLINICAL PHARMACOLOGY; PHARMACOKINETICS AND METABOLISM.) While symmetric (same dose AM and PM), around-the-clock, q12h dosing is appropriate for the majority of patients, some patients may benefit from asymmetric (different dose given in AM than in PM) dosing, tailored to their pain pattern. It is usually appropriate to treat a patient with only one opioid for around-the-clock therapy.

Initiation of Therapy

It is critical to initiate the dosing regimen for each patient individually, taking into account the patient's prior opioid and non-opioid analgesic treatment. Attention should be given to:

- (1) the general condition and medical status of the patient
- (2) the daily dose, potency and kind of the analgesic(s) the patient has been taking
- (3) the reliability of the conversion estimate used to calculate the dose of oxycodone
- (4) the patient's opioid exposure and opioid tolerance (if any)
- (5) the balance between pain control and adverse experiences

Care should be taken to use low initial doses of OxyContin in patients who are not already opioid tolerant, especially those who are receiving concurrent treatment with muscle relaxants, sedatives, or other CNS active medications (see PRECAUTIONS: Drug-Drug Interactions).

Patients Not Already Taking Opioids (opioid naive)

Clinical trials have shown that patients may initiate analgesic therapy with OxyContin. A reasonable starting dose for most patients who are opioid naive is 10 mg q12h. If a non-opioid analgesic [aspirin (ASA), acetaminophen (APAP) or a non-steroidal anti-inflammatory (NSAID)] is being provided, it may be continued. If the current non-opioid is discontinued, early upward dose titration may be necessary.

Conversion from Fixed-Ratio Opioid/APAP, ASA, or NSAID Combination Drugs

Patients who are taking 1 to 5 tablets/capsules/caplets per day of a regular strength fixed-combination opioid/non-opioid should be started on 10 to 20 mg OxyContin q12h. For patients taking 6 to 9 tablets/capsules/caplets, a starting dose of 20 to 30 mg q12h is suggested. For those taking 10 to 12 tablets, caplets or capsules a day, 30 to 40 mg q12h should be considered. The non-opioid may be continued as a separate drug. Alternatively, a different non-opioid analgesic may be selected.

If the decision is made to discontinue the non-opioid analgesic, consideration should be given to early upward titration.

Patients Currently on Opioid Therapy

If a patient has been receiving opioid-containing medications prior to OxyContin therapy, the total daily (24-hour) dose of the other opioids should be determined.

1. Using standard conversion ratio estimates (see Table 3 below), multiply the mg/day of the previous opioids by the appropriate multiplication factors to obtain the equivalent total daily dose of oral oxycodone.
2. Divide this 24-hour oxycodone dose in half to obtain the twice a day (q12h) dose of OxyContin.
3. Round down to a dose which is appropriate for the tablet strengths available (10, 20, 40, and 80 mg tablets).
4. Discontinue all other around-the-clock opioid drugs when OxyContin therapy is initiated.

No fixed conversion ratio is likely to be satisfactory in all patients, especially patients receiving large opioid doses. The recommended doses shown in Table 3 are only a starting point, and close observation and frequent titration are indicated until patients are stable on the new therapy.

Table 3
*Multiplication Factors for Converting the Daily Dose of Prior Opioids to the Daily Dose of Oral Oxycodone**
(Mg/Day Prior Opioid × Factor=Mg/Day Oral Oxycodone)

	Oral Prior Opioid	Parenteral Prior Opioid
Oxycodone	1	—
Codeine	0.15	—
Fentanyl TTS	SEE BELOW	SEE BELOW
Hydrocodone	0.9	—
Hydromorphone	4	20
Levorphanol	7.5	15
Meperidine	0.1	0.4
Methadone	1.5	3
Morphine	0.5	3

* To be used only for conversion to oral oxycodone. For patients receiving high-dose parenteral opioids, a more conservative conversion is warranted. For example, for high-dose parenteral morphine, use 1.5 instead of 3 as a multiplication factor.

In all cases, supplemental analgesia (see below) should be made available in the form of immediate-release oral oxycodone or another suitable short-acting analgesic.

OxyContin can be safely used concomitantly with usual doses of non-opioid analgesics and analgesic adjuvants, provided care is taken to select a proper initial dose (see PRECAUTIONS).

Conversion from Transdermal Fentanyl to OxyContin

Eighteen hours following the removal of the transdermal fentanyl patch, OxyContin treatment can be initiated. Although there has been no systematic assessment of such conversion, a conservative oxycodone dose, approximately 10 mg q12h of OxyContin, should be initially substituted for each 25 µg/hr fentanyl transdermal patch. The patient should be followed closely for early titration as there is very limited clinical experience with this conversion.

Managing Expected Opioid Adverse Experiences

Most patients receiving opioids, especially those who are opioid naive, will experience side effects. Frequently the side effects from OxyContin are transient, but may require evaluation and management. Adverse events such as constipation should be anticipated and treated aggressively and prophylactically with a stimulant laxative and/or stool softener. Patients do not usually become tolerant to the constipating effects of opioids.

Other opioid-related side effects such as sedation and nausea are usually self-limited and often do not persist beyond the first few days. If nausea persists and is unacceptable to the patient, treatment with anti-emetics or other modalities may relieve these symptoms and should be considered. Patients receiving OxyContin may pass an intact matrix "ghost" in the stool or via colostomy. These ghosts contain little or no residual oxycodone and are of no clinical consequence.

Individualization of Dosage

Once therapy is initiated, pain relief and other opioid effects should be frequently assessed. Patients should be titrated to adequate effect (generally mild or no pain with the regular use of no more than two doses of supplemental analgesia per 24 hours). Rescue medication should be available (see: Supplemental Analgesia). Because steady-state plasma concentrations are approximated within 24 to 36 hours, dosage adjustment may be carried out every 1 to 2 days. It is most appropriate to increase the q12h dose, not the dosing frequency. There is no clinical information on dosing intervals shorter than q12h. As a guideline, except for the increase from 10 mg to 20 mg q12h, the total daily oxycodone dose usually can be increased by 25% to 50% of the current dose at each increase.

If signs of excessive opioid-related adverse experiences are observed, the next dose may be reduced. If this adjustment

leads to inadequate analgesia, a supplemental dose of immediate-release oxycodone may be given. Alternatively, non-opioid analgesic adjuvants may be employed. Dose adjustments should be made to obtain an appropriate balance between pain relief and opioid-related adverse experiences. If significant adverse events occur before the therapeutic goal of mild or no pain is achieved, the events should be treated aggressively. Once adverse events are under control, upward titration should continue to an acceptable level of pain control.

During periods of changing analgesic requirements, including initial titration, frequent contact is recommended between physician, other members of the health-care team, the patient and the caregiver/family.

Special Instructions for OxyContin® 80 mg Tablets (For use in opioid tolerant patients only.)

OxyContin® 80 mg Tablets are for use only in opioid tolerant patients requiring daily oxycodone equivalent dosages of 160 mg or more. Care should be taken in the prescription of this tablet strength. Patients should be instructed against use by individuals other than the patient for whom it was prescribed, as such inappropriate use may have severe medical consequences.

Supplemental Analgesia

Most cancer patients given around-the-clock therapy with controlled-release opioids will need to have immediate-release medication available for "rescue" from breakthrough pain or to prevent pain that occurs predictably during certain patient activities (incident pain).

Rescue medication can be immediate-release oxycodone, either alone or in combination with acetaminophen, aspirin or other NSAIDs as a supplemental analgesic. The supplemental analgesic should be prescribed at 1/4 to 1/3 of the 12-hour OxyContin dose as shown in Table 4. The rescue medication is dosed as needed for breakthrough pain and administered one hour before anticipated incident pain. If more than two doses of rescue medication are needed within 24 hours, the dose of OxyContin should be titrated upward. Caregivers and patients using prn rescue analgesia in combination with around-the-clock opioids should be advised to report incidents of breakthrough pain to the physician managing the patient's analgesia (see Information for Patients/Caregivers).

Table 4
Table of Appropriate Supplemental Analgesia

OxyContin q12h Dose (mg)	prn Rescue Dose immediate-release oxycodone (mg)
10 (1×10 mg)	5
20 (2×10 mg)	5
30 (3×10 mg)	10
40 (2×20 mg)	10
60 (3×20 mg)	15
80 (2×40 mg)	20
120 (3×40 mg)	30
160 (2×80 mg)	40
240 (3×80 mg)	60

Maintenance of Therapy

The intent of the titration period is to establish a patient-specific q12h dose that will maintain adequate analgesia with acceptable side effects for as long as pain relief is necessary. Should pain recur then the dose can be incrementally increased to re-establish pain control. The method of therapy adjustment outlined above should be employed to re-establish pain control.

During chronic therapy, especially for non-cancer pain syndromes, the continued need for around-the-clock opioid therapy should be reassessed periodically (e.g., every 6 to 12 months) as appropriate.

Cessation of Therapy

When the patient no longer requires therapy with OxyContin tablets, patients receiving doses of 20-60 mg/day can usually have the therapy stopped abruptly without incident. However, higher doses should be tapered over several days to prevent signs and symptoms of withdrawal in the physically dependent patient. The daily dose should be reduced by approximately 50% for the first two days and then reduced by 25% every two days thereafter until the total dose reaches the dose recommended for opioid naive patients (10 or 20 mg q12h). Therapy can then be discontinued.

If signs of withdrawal appear, tapering should be stopped. The dose should be slightly increased until the signs and symptoms of opioid withdrawal disappear. Tapering should then begin again but with longer periods of time between each dose reduction.

Conversion from OxyContin to Parenteral Opioids

To avoid overdose, conservative dose conversion ratios should be followed. Initiate treatment with about 50% of the estimated equianalgesic daily dose of parenteral opioid divided into suitable individual doses based on the appropriate dosing interval, and titrate based upon the patient's response.

Continued on next page

OxyContin—Cont.**SAFETY AND HANDLING**

OxyContin® (oxycodone hydrochloride controlled-release) tablets are solid dosage forms that pose no known health risk to health-care providers beyond that of any controlled substance. As with all such drugs, care should be taken to prevent diversion or abuse by proper handling.

HOW SUPPLIED

OxyContin® (oxycodone hydrochloride controlled-release) 10 mg tablets are round, unscored, white-colored, convex tablets bearing the symbol OC on one side and 10 on the other. They are supplied as follows:

NDC 59011-100-10: child-resistant closure, opaque plastic bottles of 100

NDC 59011-100-25: unit dose packaging with 25 individually numbered tablets per card; one card per glue end carton OxyContin® (oxycodone hydrochloride controlled-release) 20 mg tablets are round, unscored, pink-colored, convex tablets bearing the symbol OC on one side and 20 on the other. They are supplied as follows:

NDC 59011-103-10: child-resistant closure, opaque plastic bottles of 100

NDC 59011-103-25: unit dose packaging with 25 individually numbered tablets per card; one card per glue end carton OxyContin® (oxycodone hydrochloride controlled-release) 40 mg tablets are round, unscored, yellow-colored, convex tablets bearing the symbol OC on one side and 40 on the other. They are supplied as follows:

NDC 59011-105-10: child-resistant closure, opaque plastic bottles of 100

NDC 59011-105-25: unit dose packaging with 25 individually numbered tablets per card; one card per glue end carton OxyContin® (oxycodone hydrochloride controlled-release) 80 mg tablets are round, unscored, green-colored, convex tablets bearing the symbol OC on one side and 80 on the other. They are supplied as follows:

NDC 59011-107-10: child-resistant closure, opaque plastic bottles of 100

NDC 59011-107-25: unit dose packaging with 25 individually numbered tablets per card; one card per glue end carton Store tablets at controlled room temperature 15–30°C (59–86°F).

Dispense in tight, light-resistant container.

CAUTION

DEA Order Form Required.

Federal law prohibits dispensing without prescription.

Manufactured by The PF Laboratories, Inc.

Totowa, N.J. 07512

Distributed by Purdue Pharma L.P.

Norwalk, CT 06850-3590

Copyright© 1995, 1997 Purdue Pharma L.P.

U.S. Patent Numbers 4,861,598; 4,970,075; 5,266,331;

5,508,042; 5,549,912.

Other Patents Pending

July 29, 1997

F4909-811

Shown in Product Identification Guide, page 333

OXYIR®
(oxycodone hydrochloride)
Immediate-Release Oral Capsules
5 mg

Ⓒ Ⓐ


OXYFAST™
(oxycodone hydrochloride)
Immediate-Release
Oral CONCENTRATE Solution*
20 mg/1mL

Ⓒ Ⓐ

*This product contains dry natural rubber

DESCRIPTION

Oxycodone is 14-hydroxydihydrocodeinone, a white odorless crystalline powder which is derived from the opium alkaloid, thebaine, and may be represented by the following structural formula:

**OxyIR Oral Capsules**

Each 5 mg of OxyIR Capsules contains:

Oxycodone hydrochloride 5 mg

Inactive ingredients: Hydroxypropyl methylcellulose, Maize starch, Polyethylene glycol, Polysorbate 80, Sucrose, Synthetic red iron oxide E172, Synthetic yellow iron oxide E172, Titanium dioxide E171.

OxyFAST Oral CONCENTRATE Solution

Each 1 mL of OxyFAST Concentrate Solution contains:

Oxycodone hydrochloride 20 mg

Inactive ingredients: Citric acid, FD&C Yellow #10, Sodium benzoate, Sodium citrate, Sodium saccharine and water.

ACTIONS

The analgesic ingredient, oxycodone, is a semisynthetic narcotic with multiple actions qualitatively similar to those of morphine; the most prominent of these involve the central nervous system and organs composed of smooth muscle. The principal actions of therapeutic value of oxycodone are analgesia and sedation.

CLINICAL PHARMACOLOGY

Central Nervous System: Oxycodone is a pure agonist opioid whose principal therapeutic action is analgesia. Other therapeutic effects of oxycodone include anxiolysis, euphoria and feelings of relaxation. Like all pure opioid agonists, there is no ceiling effect to analgesia, such as is seen with partial agonists or non-opioid analgesics.

The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and play a role in the analgesic effects of this drug.

Oxycodone produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves both a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation.

Oxycodone depresses the cough reflex by direct effect on the cough center in the medulla. Antitussive effects may occur with doses lower than those usually required for analgesia. Oxycodone causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic. Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations.

Gastrointestinal Tract and Other Smooth Muscle: Oxycodone causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid-induced effects may include a reduction in gastric, biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase.

Cardiovascular System: Oxycodone may produce release of histamine with or without associated peripheral vasodilation. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.

Concentration—Efficacy Relationships (Pharmacodynamics): Studies in normal volunteers and patients reveal predictable relationships between oxycodone dosage and plasma oxycodone concentrations, as well as between concentration and certain expected opioid effects. In normal volunteers these include pupillary constriction, sedation and overall "drug effect" and in patients, analgesia and feelings of "relaxation." In nontolerant patients, analgesia is not usually seen at a plasma oxycodone concentration of less than 5–10 ng/mL.

As with all opioids, the minimum effective plasma concentration for analgesia will vary widely among patients, especially among patients who have been previously treated with potent agonist opioids. As a result, patients need to be treated with individualized titration of dosage to the desired effect. The minimum effective analgesic concentration of oxycodone for any individual patient may increase with repeated dosing due to an increase in pain and/or the development of tolerance.

Concentration—Adverse Experience Relationships: OxyIR Capsules and OxyFAST CONCENTRATE Solution are associated with typical opioid-related adverse experiences similar to those seen with all opioids. There is a general relationship between increasing oxycodone plasma concentration and increasing frequency of dose-related opioid adverse experiences such as nausea, vomiting, CNS effects and respiratory depression. In opioid-tolerant patients, the situation is altered by the development of tolerance to opioid-related side effects, and the relationship is poorly understood.

As with all opioids, the dose must be individualized (see DOSAGE AND ADMINISTRATION), because the effective analgesic dose for some patients will be too high to be tolerated by other patients.

INDICATIONS AND USAGE

For the relief of moderate to moderately severe pain.

CONTRAINDICATIONS

OxyIR and OxyFAST is contraindicated in patients with known hypersensitivity to oxycodone, or in any situation where opioids are contraindicated. This includes patients with significant respiratory depression (in unmonitored settings or the absence of resuscitative equipment), and patients with acute or severe bronchial asthma or hypercarbia. OxyIR and OxyFAST are contraindicated in any patient who has or is suspected of having paralytic ileus.

WARNINGS

Respiratory Depression: Respiratory depression is the chief hazard from all opioid agonist preparations. Respiratory depression occurs most frequently in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other agents that depress respiration.

Oxycodone should be used with extreme caution in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and in patients having a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression. In such patients, even usual therapeutic doses of oxycodone may decrease respiratory drive to the point of apnea. In these patients alternative non-opioid analgesics should be considered, and opioids should be employed only under careful medical supervision at the lowest effective dose.

Hypotensive Effect: OxyIR and OxyFAST, like all opioid analgesics, may cause severe hypotension in an individual whose ability to maintain blood pressure has been compromised by a depleted blood volume, or after concurrent administration with drugs such as phenothiazines or other agents which compromise vasomotor tone. OxyIR and OxyFAST may produce orthostatic hypotension in ambulatory patients. OxyIR and OxyFAST, like all opioid analgesics, should be administered with caution to patients in circulatory shock, since vasodilation produced by the drug may further reduce cardiac output and blood pressure.

Drug Dependence: Oxycodone can produce drug dependence of the morphine type, and therefore, has the potential for being abused. Psychic dependence, physical dependence and tolerance may develop upon repeated administration of this drug, and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral narcotic-containing medications. Like other narcotic-containing medications, this drug is subject to the federal Controlled Substances Act.

Usage in Ambulatory Patients: Oxycodone may impair the mental and/or physical abilities required for the performance of potential hazardous tasks such as driving a car or operating machinery. The patient using this drug should be cautioned accordingly.

Interaction with Other Central Nervous System Depressants: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with oxycodone hydrochloride may exhibit an additive CNS depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced.

Usage in Pregnancy: Safe use in pregnancy has not been established relative to possible adverse effects on fetal development. Therefore, this drug should not be used in pregnant women unless, in the judgment of the physician, the potential benefits outweigh the possible hazards.

Usage in Children: This drug should not be administered to children.

PRECAUTIONS

Special Precautions Regarding OxyFAST Oral CONCENTRATE 20 mg/1 mL Solution

OxyFAST 20 mg/1mL solution is a highly concentrated solution. Care should be taken in the prescription and dispensing of this solution strength. Patients should be instructed against use by individuals other than the patient, as inappropriate use may cause acute overdose.

General

Opioid analgesics given on a fixed-dosage schedule have a narrow therapeutic index in certain patient populations, especially when combined with other drugs, and should be reserved for cases where the benefits of opioid analgesia outweigh the known risks of respiratory depression, altered mental state, and postural hypotension.

Use of OxyIR and OxyFAST is associated with increased potential risks and should be used only with caution in the following conditions: acute alcoholism; adrenocortical insufficiency (e.g., Addison's disease); CNS depression or coma; delirium tremens; debilitated patients; kyphoscoliosis associated with respiratory depression; myxedema or hypothyroidism; prostatic hypertrophy or urethral stricture; severe impairment of hepatic, pulmonary or renal function; and toxic psychosis.

The administration of oxycodone, like all opioid analgesics, may obscure the diagnosis or clinical course in patients with acute abdominal conditions. Oxycodone may aggravate con-